Trump GLP-1 Deal Leaves Medicare Price Cut Contingent on Private Plan Copays
A contingency clause in the Trump administration GLP-1 agreement with Lilly and Novo allowed manufacturers to gain Medicare and Medicaid volume at $245 monthly without guaranteeing the linked $50 Medicare Advantage copay. Fewer than 30 percent of plans have adopted broad coverage, preserving higher costs for millions. The structure will directly affect 2027 plan bids and beneficiary access.
The STAT reporting reveals that Eli Lilly and Novo Nordisk secured expanded Medicare and Medicaid volume at the negotiated $245 price while the lower-price condition hinged on separate negotiations with Medicare Advantage insurers. Those insurers have not uniformly adopted the $50 copay requirement, allowing list prices or higher negotiated rates to persist for many beneficiaries. This structure effectively decoupled volume gains from the intended system-wide price reduction.
Related CMS guidance from early 2026 and a Kaiser Family Foundation analysis of 2025 Medicare Advantage formulary filings show that fewer than 30 percent of plans had added broad GLP-1 obesity coverage by the first quarter of 2026. Plans cited actuarial uncertainty and rebate retention as reasons for delay, confirming the contingency clause created a practical barrier rather than an automatic price floor.
The loophole will shape 2027 open enrollment because Medicare Advantage bids due in June 2026 must reflect actual formulary decisions. If uptake remains below the threshold implied by the original deal, manufacturers retain pricing flexibility while still counting expanded Medicaid populations toward their volume commitments.
Patients in traditional Medicare without supplemental coverage face the largest immediate exposure, as Part D plans can apply the full negotiated rate absent the $50 copay mandate.
CMS Administrator: Medicare Advantage GLP-1 obesity coverage will remain below 35 percent of plans through the 2027 bid cycle unless CMS issues new guidance by September 2026.
Sources (3)
- [1]STAT News(https://www.statnews.com/2026/06/30/medicare-medicaid-glp1-costs-explained-balance-out-bridge-in/)
- [2]Kaiser Family Foundation Medicare Advantage Formulary Analysis(https://www.kff.org/medicare/issue-brief/medicare-advantage-formulary-analysis-2026/)
- [3]CMS Medicare Advantage Bid Guidance 2026(https://www.cms.gov/files/document/2026-ma-bid-instructions.pdf)